Catalent Announces Appointment of Sally Langa
News Jan 29, 2016
Catalent Pharma Solutions has announced the appointment of Sally Langa to the position of Vice President, Business Development, for Catalent’s Development and Analytical Services offerings. In this role, Ms. Langa will be responsible for growing Catalent’s early phase development business for small molecule compounds, including analytical services, formulation development, and micronization.
Ms. Langa joins Catalent from Halo Pharma where she held the role of Vice President, Sales and Marketing. Her career within the pharmaceutical services industry, which spans almost thirty years, has also seen her hold a number of senior positions at Patheon.
“Sally brings a huge amount of experience to Catalent and will be a pivotal part of the team charged with meeting the company’s ambitious growth targets,” commented Jonathan Arnold, Vice President and General Manager of Advanced Delivery Technologies. “Catalent sees great growth potential in its early stage development activities, as well as continued opportunity to integrate these services further into the clinical and commercial phases of development.”
Ms. Langa is an active member of the Drug, Chemical and Associated Technologies (DCAT) Association, and is currently on the Technology Committee. She is also a Trustee on the Board of the Pharma & Biopharma Outsourcing Association (PBOA).
Catalent’s Development and Analytical services, located at sites throughout the US and Europe, offer global solutions with specialty handling capabilities for controlled substances, highly potent, cytotoxic, and temperature critical compounds, to handle the most challenging molecules.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE